XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:      
Net loss $ (45,117,000) $ (17,971,000) $ (14,704,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock option compensation expense 50,000 161,000 349,000
Restricted stock compensation expense 79,000 266,000 308,000
Depreciation expense 310,000 305,000 617,000
Loss on disposal of equipment 18,000 1,000 15,000
Warrant liability fair value adjustment (15,103,000) (12,780,000) (564,000)
Gain on warrant extinguishment (9,613,000) 0 0
Non-cash interest income (1,000) (1,000) (1,000)
Debt discount and deferred finance costs amortization 21,544,000 14,268,000 0
Loss on debt settlements and extinguishments 29,924,000 0 0
Changes in assets and liabilities:      
Decrease in prepaid expenses and other assets 7,000 260,000 9,000
(Increase) decrease in accounts receivable 108,000 (138,000) (52,000)
Decrease (increase) in inventories (543,000) 95,000 (420,000)
Increase (decrease) in accounts payable and accrued expenses 3,180,000 1,507,000 (1,757,000)
Increase (decrease) in deferred revenue (32,000) 30,000 0
Decrease in other non-current liabilities (209,000) (216,000) (220,000)
Net cash used in operating activities (15,398,000) (14,213,000) (16,420,000)
Cash flows from investing activities:      
Purchase of property, plant and equipment (524,000) (258,000) (170,000)
Increase in restricted cash 0 (1,087,000) 0
Proceeds from sales of property, plant and equipment 0 0 180,000
Net cash (used in) provided by investing activities (524,000) (1,345,000) 10,000
Cash flows from financing activities:      
Increase in restricted cash 0 (26,200,000) 0
Net proceeds from the release of restricted cash 13,120,000 0 0
Net proceeds from sale of Series B and Series C preferred shares 2,310,000 0 0
Net proceeds from convertible note debt financing 0 31,226,000 0
Net proceeds from sale of stock and exercise of warrants 15,000 2,383,000 8,655,000
Net cash provided by financing activities 15,445,000 7,409,000 8,655,000
Fx effect on cash 67,000 (49,000) (107,000)
Increase (decrease) in cash and cash equivalents (410,000) (8,198,000) (7,862,000)
Cash and cash equivalents at beginning of period 4,409,000 12,607,000 20,469,000
Cash and cash equivalents at end of period 3,999,000 4,409,000 12,607,000
Supplemental non-cash activities:      
Conversion of convertible notes 40,121,000 649,000 0
Fair value of warrants issued 16,953,000 28,472,000 4,247,000
Cashless exercise of warrants 2,537,000 0 0
Deemed dividend 527,000 0 0
Fair value of warrants exercised for cash 19,000 726,000 123,000
Series A and Series B Preferred Shares [Member]      
Cash flows from financing activities:      
Release of restricted cash for redemption of preferred shares 2,360,000 0 0
Cash paid to redeem preferred shares (2,360,000) 0 0
Series C Preferred Shares [Member]      
Cash flows from financing activities:      
Release of restricted cash for redemption of preferred shares 590,000 0 0
Cash paid to redeem preferred shares (590,000) 0 0
Series C Warrants [Member]      
Cash flows from financing activities:      
Release of restricted cash for extinguishment of Series C Warrants 7,876,000 0 0
Cash paid to extinguish of Series C Warrants $ (7,876,000) $ 0 $ 0